natgillin/translations-raw huggingface dataset:
A crossover study in 40 healthy subjects, 10 each in the four CYP2C19 metaboliser groups (ultrarapid, extensive, intermediate and poor), evaluated pharmacokinetic and antiplatelet responses using 300 mg followed by 75 mg/day and 600 mg followed by 150 mg/day, each for a total of 5 days (steady state).
Ravimi ristvahetusega uuringus hinnati 40 tervel uuritaval (10 igast neljast CYP2C19 metabolismigrupist – ülikiire, ulatuslik, vahepealne ja puudulik) farmakokineetikat ja trombotsüütide ravivastust pärast klopidogreeli manustamist annuses 300 mg ja seejärel 75 mg üks kord ööpäevas ning 600 mg ja seejärel 150 mg ööpäevas, kumbki kokku 5 päeva kuni püsitasakaalu saavutamiseni.
A crossover study in 40 healthy subjects, 10 each in the four CYP2C19 metaboliser groups (ultrarapid, extensive, intermediate and poor), evaluated pharmacokinetic and antiplatelet responses using 300 mg followed by 75 mg/day and 600 mg followed by 150 mg/day, each for a total of 5 days (steady state).
Ravimi ristvahetusega uuringus hinnati 40 tervel uuritaval (10 igast neljast CYP2C19 metabolismigrupist – ülikiire, ulatuslik, vahepealne ja puudulik) farmakokineetikat ja trombotsüütide ravivastust pärast klopidogreeli manustamist annuses 300 mg ja seejärel 75 mg üks kord ööpäevas ning annuses 600 mg ja seejärel 150 mg ööpäevas, kumbki kokku 5 päeva kuni püsitasakaalu saavutamiseni.
A cumulative review of bronchoconstriction was also conducted.
Vaadati läbi ka kumulatiivsed bronhokonstriktsiooni juhtumid.
A cut-off of >2% was applied
Kohaldati piirmäära > 2
A CYP3A4 inducer, rifampicin (600 mg daily), reduced tadalafil AUC by 88 % and Cmax by 46 %, relative to the AUC and Cmax values for tadalafil alone (10 mg).
CYP3A4 indutseerija, rifampitsiin (600 mg päevas), vähendas tadalafiili AUC 88 % võrra ja Cmax 46 % võrra, võrreldes ainult tadalafiili (10 mg) AUC ja Cmax väärtustega.
A daily dose from 400 mg per day (2 tablets) to 1200 mg per day (6 tablets) taken orally in 2 to 3 divided doses may be required to restore your normal cortisol levels.
Tavapärase kortisoolitaseme taastamiseks võib olla vajalik suu kaudu võetav 2–3 väiksemaks annuseks jagatud igapäevane annus alates 400 mg ööpäevas (2 tabletti) kuni 1200 mg ööpäevas (6 tabletti).
A daily increase of oestradiol levels of
Päevaseks östradiooli sisalduse optimaalseks juurdekasvuks on 40…100%.
A daily increase of oestradiol levels of 40- 100% is considered to be optimal.
Päevaseks östradiooli sisalduse optimaalseks juurdekasvuks on 40…100%.
A daily regimen of 150 mg of Wilzin in three administrations was shown to be effective in significantly reducing copper absorption and inducing a negative copper balance.
Näidati, et Wilzin’i kasutamine 150 mg päevas kolme annusena vähendas oluliselt vase imendumist ja tekitas vase negatiivse bilansi.
A dark yellow film-coated, tapered oblong shaped, biconvex tablet debossed with “ME” on the left of the score and “10” on the right of the score on one side of the tablet and a score on the other side.
Tumekollane õhukese polümeerikattega teravate otstega piklik kaksikkumer tablett, mille ühel küljel on poolitusjoonest vasakule pressitud „ME” ja paremale pressitud „10” ning teisel küljel on poolitusjoon.
A dark yellow film-coated, tapered oblong shaped, biconvex tablet marked with “ME” on the left of the score and “10” on the right of the score on one side of the tablet and a score on the other side.
Tumekollane õhukese polümeerikattega teravate otstega piklik kaksikkumer tablett, mille ühel küljel on poolitusjoonest vasakule pressitud „ME” ja paremale pressitud „10” ning teisel küljel on poolitusjoon.
a DAS28-defined remission (DAS28-CRP <2.6) b SDAI criterion (SDAI ≤ 3.3)
a DAS28 alusel määratletud remissioon (DAS28-CRP < 2,6) b SDAI kriteerium (SDAI ≤ 3,3)
a Day 169 Last Observation Carried Forward (LOCF) for patients treated in Period C b As observed
a Päev 169 Viimane edasikantud väärtus (Last Observation Carried Forward) (LOCF) Perioodil C ravitud patsiendid b hinnanguliselt
A decision about using this vaccine before or after any other veterinary medicinal product therefore needs to be made by the responsible veterinarian on a case by case basis.
Seetõttu peab otsuse selle vaktsiini kasutamise kohta enne või pärast mistahes muud veterinaarravimit tegema vastutav veterinaararst igal erineval juhul eraldi.
A decision must be made by your doctor whether to discontinue breast-feeding or to discontinue/abstain from Trajenta therapy.
Teie arst peab otsustama, kas katkestada imetamine või katkestada/hoiduda ravist Trajenta’ga.
A decision must be made on whether to continue/discontinue breast-feeding or to continue/discontinue therapy with NeuroBloc taking into account the benefit of breast-feeding to the child and the benefit of NeuroBloc therapy to the woman.
Tuleb otsustada, kas katkestada rinnaga toitmine või jätta ära ravi NeuroBloc’iga sõltuvalt ravimist saadavast kasust emale ja rinnaga toitmise olulisusest lapsele.
A decision must be made whether to continue/discontinue breast-feeding or to continue/discontinue therapy with Xydalba taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.
Rinnaga toitmise katkestamine või ravi katkestamine/jätkamine ravimiga Xydalba, tuleb otsustada arvestades imetamise kasu lapsele ja ravi kasu naisele.
A decision must be made whether to discontinue breast feeding or to discontinue/abstain from therapy.
Tuleb otsustada, kas katkestada rinnaga toitmine või katkestada/vältida ravi.
A decision must be made whether to discontinue breast- feeding or to discontinue from LUMIGAN therapy taking into account the benefit of breast feeding for the child and the benefit of therapy for the woman.
Rinnaga toitmise katkestamine või ravi katkestamine LUMIGAN’iga tuleb otsustada, arvestades imetamise kasu lapsele ja ravi kasu naisele.
A decision must be made whether to discontinue breast- feeding or to discontinue from LUMIGAN therapy taking into account the benefit of breast feeding for the child and the benefit of therapy for the woman.
Rinnaga toitmise katkestamine või ravi katkestamine/jätkamine LUMIGAN’iga, tuleb otsustada arvestades imetamise kasu lapsele ja ravi kasu naisele.
A decision must be made whether to discontinue breast- feeding or to discontinue/abstain from Abilify Maintena therapy taking into account the benefit of breast feeding for the child and the benefit of therapy for the woman.
Tuleb otsustada, kas lõpetada imetamine või lõpetada/hoiduda Abilify Maintena-ravist, arvestades imetamise kasu lapsele ja ravi kasu naisele.
A decision must be made whether to discontinue breast- feeding or to discontinue/abstain from Desloratadine Teva 5 mg film-coated tablets therapy taking into account the benefit of breast feeding for the child and the benefit of therapy for the woman.
Rinnaga toitmise katkestamine või ravi katkestamine/jätkamine Desloratadine Teva 5 mg õhukese polümeerikattega tablettidega tuleb otsustada, arvestades imetamise kasu lapsele ja ravi kasu naisele.
A decision must be made whether to discontinue breast- feeding or to discontinue/abstain from filgrastim therapy taking into account the benefit of breast feeding for the child and the benefit of therapy for the woman.
Rinnaga toitmise katkestamine või ravi katkestamine/jätkamine, tuleb otsustada arvestades imetamise kasu lapsele ja ravi kasu naisele.
A decision must be made whether to discontinue breast- feeding or to discontinue/abstain from glycerol phenylbutyrate therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.
Rinnaga toitmise katkestamine või ravi katkestamine/jätkamine glütseroolfenüülbutüraadiga tuleb otsustada, arvestades imetamise kasu lapsele ja ravi kasu naisele.
A decision must be made whether to discontinue breast- feeding or to discontinue/abstain from therapy.
Tuleb otsustada, kas katkestada rinnaga toitmine või katkestada/vältida ravi.
A decision must be made whether to discontinue breast-feeding or discontinue/abstain from Repatha therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.
Peab otsustama, kas loobuda rinnaga toitmisest või ravist Repatha’ga, arvestades imetamise kasu lapsele ja ravi kasu naisele.
A decision must be made whether to discontinue breast-feeding or discontinue/abstain from Zykadia therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman (see section 5.3).
Rinnaga toitmise katkestamine või ravi katkestamine/jätkamine Zykadia’ga, tuleb otsustada arvestades imetamise kasu lapsele ja ravi kasu naisele (vt lõik 5.3).
A decision must be made whether to discontinue breast-feeding or to abstain from Eylea therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.
Võttes arvesse nii imetamise kasulikkust lapsele kui ka ravist saadavat kasu naisele, tuleb otsustada, kas katkestada rinnaga toitmine või hoiduda Eylea- ravist.
A decision must be made whether to discontinue breast-feeding or to continue/abstain from Revolade therapy, taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.
Tuleb teha otsus, kas lõpetada rinnaga toitmine või jätkata / loobuda ravist Revolade’ga, võttes arvesse rinnaga toitmisest saadavat kasu lapsele ja ravist saadavat kasu naisele.
A decision must be made whether to discontinue breast-feeding or to discontinue from LUMIGAN therapy taking into account the benefit of breast- feeding for the child and the benefit of therapy for the woman.
Rinnaga toitmise katkestamine või ravi katkestamine/jätkamine LUMIGAN’iga, tuleb otsustada arvestades imetamise kasu lapsele ja ravi kasu naisele.
A decision must be made whether to discontinue breast-feeding or to discontinue Incruse therapy taking into account the benefit of breastfeeding for the child and the benefit of therapy for the woman.
Tuleb teha otsus, kas lõpetada rinnaga toitmine või ravi Incruse’ga, arvestades rinnaga toitmisest saadavat kasu lapsele ja ravist saadavat kasu naisele.
A decision must be made whether to discontinue breast-feeding or to discontinue Nucala therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.
Rinnaga toitmise katkestamine või Nucala-ravi katkestamine tuleb otsustada arvestades imetamise kasu lapsele ja ravi kasu naisele.
A decision must be made whether to discontinue breast-feeding or to discontinue therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy to the woman.
Rinnaga toitmise katkestamine või ravi katkestamine/jätkamine, tuleb otsustada arvestades imetamise kasu lapsele ja ravi kasu naisele.
A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from Aranesp therapy taking into account the benefit of breast feeding for the child and the benefit of therapy for the woman.
Peab otsustama, kas katkestada imetamine või katkestada/mitte alustada ravi Aranesp’iga, arvestades imetamise kasu lapsele ja ravi kasu naisele.
A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from ATryn therapy taking into account the benefit of breastfeeding for the child and the benefit of therapy for the woman.
Otsuse tegemisel, kas katkestada imetamine või katkestada/vältida ravi ATryn’iga, tuleb kaaluda imetamise kasu lapsele ja ravi kasu naisele.
A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from AZARGA therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.
Rinnaga toitmise katkestamine või ravi katkestamine AZARGA’ga tuleb otsustada arvestades imetamise kasu lapsele ja ravi kasu naisele.
A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from AZOPT therapy taking in to account the benefit of breast- feeding for the child and the benefit of therapy for the woman.
Arst peab otsustama, kas katkestada imetamine või katkestada AZOPTi kasutamine / loobuda AZOPTi kasutamisest, võttes arvesse rinnaga toitmise kasulikkust lapsele ja ravist saadavat kasu naisele.
A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from Brintellix treatment taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.
Tuleb teha otsus, kas lõpetada rinnaga toitmine või lõpetada/loobuda ravist Brintellix’iga, võttes arvesse rinnaga toitmisest saadavat kasu lapsele ja ravist saadavat kasu naisele.
A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from Cerdelga therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.
Tuleb otsustada, kas katkestada rinnaga toitmine või katkestada (mitte alustada) ravi Cerdelga’ga, arvestades imetamise kasu lapsele ja ravi kasu naisele.
A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from DIFICLIR therapy, taking into account the benefit of breast feeding for the child and the benefit of therapy for the woman.
Rinnaga toitmise katkestamine või DIFICLIR’iga ravi katkestamine/jätkamine, tuleb otsustada arvestades imetamise kasu lapsele ja ravi kasu naisele.
A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from Filgrastim HEXAL therapy taking into account the benefit of breast feeding for the child and the benefit of therapy for the woman.
Tuleb otsustada, kas lõpetada imetamine või lõpetada ravi Filgrastim HEXAL’iga, võttes arvesse imetamisega kaasnevat kasu lapsele ja raviga kaasnevat kasu naisele.
A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from filgrastim therapy taking into account the benefit of breast feeding for the child and the benefit of therapy for the woman.
Tuleb otsustada, kas lõpetada rinnaga toitmine või lõpetada (mitte alustada) ravi filgrastiimiga, arvestades imetamise kasu lapsele ja ravi kasu naisele.
A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from Fycompa therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.
Rinnaga toitmise katkestamine või Fycompa-ravi katkestamine/jätkamine tuleb otsustada, arvestades imetamise kasu lapsele ja ravi kasu naisele.
A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from IKERVIS therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.
Rinnaga toitmise katkestamine või ravi katkestamine/jätkamine IKERVIS’ega tuleb otsustada arvestades imetamise kasu lapsele ja ravi kasu naisele.
A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from Imlygic therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.
Tuleb otsustada, kas katkestada rinnaga toitmine või katkestada/loobuda ravist Imlygic’uga, kaaludes imetamise kasulikkust lapsele ja ravi kasulikkust naisele.
A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from MULTAQ therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.
Tuleb teha otsus, kas katkestada imetamine või ravi MULTAQ’iga, arvestades imetamise kasu lapsele ja ravi kasu naisele.
A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from Neulasta therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.
Otsus loobuda imetamisest või ravist Neulasta’ga tuleb teha, lähtudes rinnaga toitmise kasust vastsündinule ja imikule ning ravi kasust emale.
A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from Rasilamlo therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.
Rinnaga toitmise katkestamine või Rasilamlo-ravi katkestamine/jätkamine tuleb otsustada arvestades imetamise kasu lapsele ja ravi kasu naisele.
A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from Ristempa therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.
Otsus loobuda imetamisest või ravist Ristempa’ga tuleb teha, lähtudes rinnaga toitmise kasust vastsündinule ja imikule ning ravi kasust emale.
A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from Selincro therapy, taking into account the benefit of breast-feeding to the child and the benefit of therapy to the woman.
Rinnaga toitmise katkestamine või Selincro-ravi katkestamine ja lõpetamine tuleb otsustada arvestades imetamise kasu lapsele ja ravi kasu naisele.
A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from Sivextro therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.
Rinnaga toitmise katkestamine või ravi katkestamine/jätkamine Sivextroga tuleb otsustada, arvestades imetamise kasu lapsele ja ravi kasu naisele.
A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from therapy with epoetin alfa taking into account the benefit of breastfeeding for the child and the benefit of epoetin alfa therapy for the woman.
Rinnaga toitmise katkestamine või alfaepoetiiniga ravi katkestamine/jätkamine, tuleb otsustada arvestades imetamise kasu lapsele ja alfaepoetiinravi kasu naisele.
A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from ticagrelor therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.
Tuleb langetada otsus, kas katkestada imetamine või ravi tikagrelooriga, arvestades imetamisest saadavat kasu lapsele ning ravist saadavat kasu naisele.
A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from ZALTRAP therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.
Peab otsustama, kas lõpetada rinnaga toitmine või lõpetada/mitte alustada ravi ZALTRAP’iga, arvestades imetamise kasu lapsele ja ravi kasu naisele.
A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from Zarzio therapy taking into account the benefit of breast feeding for the child and the benefit of therapy for the woman.
Tuleb otsustada, kas lõpetada imetamine või lõpetada ravi Zarzioga, võttes arvesse imetamisega kaasnevat kasu lapsele ja raviga kaasnevat kasu naisele.
A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from ZEPATIER therapy taking into account the benefit of breast feeding for the child and the benefit of therapy for the woman.
Tuleb langetada otsus, kas lõpetada rinnaga toitmine või katkestada ravi/loobuda ravist ZEPATIERiga, võttes arvesse imetamise kasulikkust lapsele ja ravist saadavat kasu naisele.
A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from ziconotide therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.
Rinnaga toitmise katkestamine või zikonotiidravi katkestamine/jätkamine tuleb otsustada, arvestades imetamise kasu lapsele ja ravi kasu naisele.
A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from Zinforo therapy taking into account the benefit of therapy for the woman.
Tuleb otsustada, kas katkestada imetamine või katkestada/hoiduda Zinforo-ravist, arvestades ravi kasulikkust naisele.
A decision must be made whether to discontinue breast-feeding or to not administer ZOSTAVAX taking into account the benefit of breast feeding for the child and the benefit of vaccination for the woman.
Rinnaga toitmise katkestamine või ZOSTAVAXi mittemanustamine tuleb otsustada, arvestades imetamise kasu lapsele ja vaktsineerimise kasu naisele.
A decision must be made whether to discontinue breastfeeding or to discontinue Aerivio Spiromax therapy taking into account the benefit of breastfeeding for the child and the benefit of therapy for the woman.
Rinnaga toitmise katkestamine või Airexar Spiromax-ravi katkestamine tuleb otsustada arvestades imetamise kasu lapsele ja ravi kasu naisele.
A decision on whether or not Gilenya therapy should be re-initiated after resolution of macular oedema needs to take into account the potential benefits and risks for the individual patient.
Otsus, kas pärast maakula turse alanemist ravi Gilenya’ga uuesti alustada või mitte, peab arvestama võimalikke kasusid ja riske iga patsiendi jaoks eraldi.
A decision on whether to abstain from breast-feeding or to abstain from therapy with Prolia should be made, taking into account the benefit of breast-feeding to the newborn/infant and the benefit of Prolia therapy to the woman.
Otsus loobuda imetamisest või ravist Prolia’ga tuleb teha, lähtudes rinnaga toitmise kasust vastsündinule/imikule ja Prolia’ga ravi kasust emale.
A decision on whether to abstain from breast-feeding or to abstain from therapy with XGEVA should be made, taking into account the benefit of breast- feeding to the newborn/infant and the benefit of XGEVA therapy to the woman.
Otsus loobuda imetamisest või ravist XGEVA’ga tuleb teha, lähtudes rinnaga toitmise kasust vastsündinule/imikule ja XGEVA’ga ravi kasust emale.
A decision on whether to continue or discontinue breast-feeding or to continue or discontinue therapy with MIRCERA should be made taking into account the benefit of breast-feeding to the child and the benefit of MIRCERA therapy to the woman.
Otsustamisel, kas jätkata või katkestada imetamine või jätkata või katkestada ravi MIRCERA’ga, peab arvesse võtma imetamisest saadavat kasu lapsele ja MIRCERA-ravist saadavat kasu naisele.
A decision on whether to continue/discontinue breast- feeding or therapy with anidulafungin should be made taking into account the benefit of breast-feeding to the child and the benefit of anidulafungin to the mother.
Otsus rinnaga toitmise või anidulafungiinravi jätkamise üle tuleb langetada, lähtudes rinnaga toitmise kasulikest toimetest lapsele ja anidulafungiini kasulikest toimetest emale.
A decision on whether to continue/discontinue breast- feeding or to continue/discontinue therapy with Twinrix Adult should be made taking into account the benefit of breast-feeding to the child and the benefit of Twinrix Adult therapy to the woman.
Enne otsustamist, kas jätkata Twinrix Adult vaktsiini manustamise ajal imetamist või rinnaga toitmine selleks ajaks katkestada, peab kaaluma imetamisest tulenevat kasu lapsele ja Twinrix Adult vaktsiini oodatavat kasu emale.
A decision on whether to continue/discontinue breast-feeding or to continue/discontinue therapy should be made taking into account the benefit of breast-feeding to the child and the benefit of mifamurtide therapy to the woman.
Otsus imetamise jätkamise või katkestamise või mifamurtiidravi jätkamise või katkestamise kohta tuleb teha, võttes arvesse imetamise kasulikkust lapsele ja mifamurtiidravi kasulikkust emale.
A decision on whether to continue/discontinue breast-feeding or to continue/discontinue therapy with Altargo should be made taking into account the benefit of breast-feeding to the child and the benefit of Altargo therapy to the woman.
Otsuse langetamisel, kas jätkata/katkestada rinnaga toitmine või jätkata/katkestada ravi Altargo’ga, tuleb kaaluda rinnaga toitmisest saadavat kasu lapsele ja Altargo-ravist saadavat kasu naisele.
A decision on whether to continue/discontinue breast-feeding or to continue/discontinue therapy with CHAMPIX should be made taking into account the benefit of breast-feeding to the child and the benefit of CHAMPIX therapy to the woman.
Otsuse tegemisel, kas jätkata/katkestada rinnaga toitmine või jätkata/katkestada ravi CHAMPIX’iga, peab arvesse võtma rinnaga toitmise kasulikkust lapsele ja CHAMPIX-ravist saadavat kasu naisele.